x Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials Open access logo PDF logo

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua LS, Yang LF, Brashear HR, Black RS

Alzheimer's Research & Therapy Volume 8, Issue 1, DOI: 10.1186/s13195-016-0189-7

  • 3 tweets
  • 1 news
  • 60 Mendeley readers

Geographics of Mendeley readers

By country: 5

Unknown: 55


Readers by professional status:


Readers by discipline:

Site data sourced from Altmetric.com and CSC (VIRTA)